Korea Cancer Center Hospital   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1962)

Organization Overview

First Clinical Trial
2002
NCT01097252
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Surgery, Korea Cancer Center Hospital, 215-4 Gongneung-dong, Nowon-gu, Seoul, Korea | Korea Cancer Center Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 4)

Encephalitis (Phase 3)

Encephalitis, Japanese (Phase 3)

Hot Flashes (Phase 4)

Immunoblastic Lymphadenopathy (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Ovarian Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 19